PLX Stock Risk & Deep Value Analysis
Protalix Biotherapeutics Inc
Healthcare • Biotechnology
DVR Score
out of 10
The Bottom Line on PLX
We analyzed Protalix Biotherapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran PLX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.
PLX Stock Risk Analysis
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Medium
About Protalix Biotherapeutics Inc (PLX)
Sector
Healthcare
Industry
Biotechnology
Market Cap Category
small
Market Cap
$188.17M
PLX Deep Value Analysis
Compare PLX to Similar Stocks
See how Protalix Biotherapeutics Inc stacks up against related companies in our head-to-head analysis.
PLX Red Flags & Warning Signs
- âš
Disappointing Elfabrio sales or royalty growth below expectations
- âš
Further equity dilution to fund operations
- âš
Negative clinical trial results or regulatory setbacks for pipeline candidates
- âš
Heightened competition in the Fabry disease market or target areas for pipeline
Unlock PLX Red Flags & Risk Warnings
Create a free account to see the full analysis
PLX Financial Health Metrics
Market Cap
$188.17M
P/E Ratio
26.22
PLX Competitive Moat Analysis
Sign in to unlockMoat Rating
Narrow
Moat Trend
Stable
Moat Sources
1 Identified
The ProCellEx platform, with its unique method of protein expression, offers a proprietary technology that can be difficult to replicate. This creates an intellectual property moat for potential new drug candidates. Its durability relies on continued successful drug development and market adoption.
PLX Competitive Moat Analysis
Sign up to see competitive advantages
PLX Catalysts & Growth Drivers
Near-Term (0-6 months)
- •Q4 2025 Earnings Report (Estimated Early March 2026)
- •Updates on Elfabrio's commercial performance by Chiesi Global Rare Diseases
- •Potential (minor) preclinical/early-stage pipeline data updates
Medium-Term (6-18 months)
- •Full Year 2026 Financial Outlook and Guidance
- •Advancement of an existing preclinical candidate into IND-enabling studies or Phase 1
- •Potential new (regional) partnership or expanded terms for ProCellEx platform
Long-Term (18+ months)
- •Successful Phase 2/3 clinical trial results for a new lead candidate (retaining significant commercial rights)
- •Significant market share gain for Elfabrio globally, leading to higher royalty payments
- •Strategic acquisition interest driven by the ProCellEx platform
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
PLX Bull Case: What Could Go Right
- ✓
Significant acceleration in Elfabrio royalty revenue or milestone payments
- ✓
Announcement of a new, well-structured partnership for a pipeline candidate
- ✓
Initiation of a Phase 2 or 3 clinical trial for a wholly-owned asset
- ✓
Improved cash burn rate and reduction in future dilution risk
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.
